Generex Biotechnology Corporation announced earnings results for the second quarter ended January 31, 2021. For the second quarter, the company announced sales was USD 0 compared to USD 857,427 a year ago. Operating loss was USD 8.576 million compared to USD 4.558 million a year ago. Net loss was USD 24.080 million compared to USD 6.909 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.11 a year ago. For the half year, sales was USD 88,435 compared to USD 1.579 million a year ago. Operating loss was USD 22.689 million compared to USD 9.107 million a year ago. Net loss was USD 34.811 million compared to USD 16.035 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.24 a year ago.